Clay Siegall, PhD, co-founded Seagen Inc. (formerly Seattle Genetics) in 1998 with a vision to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, he built a foundation based on a unique science-driven culture, successful drug discovery and development, and a passion for helping patients. Today, Seagen has four FDA-approved medicines and leads the field in antibody-drug conjugate (ADC) technology and development.

Prior to founding Seagen, Dr. Siegall held positions at Bristol Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, a part of the National Institutes of Health. He has authored more than 70 publications and holds 15 patents. Dr. Siegall has been recognized as an Ernst & Young Entrepreneur of the Year and the Dealmaker of the Year by the Puget Sound Business Journal.

Dr. Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He serves as chairman of the board of Umoja Biopharma as well as a member of the board of directors of Nurix Therapeutics, Inc. and Washington Roundtable.